Lyell Wealth Management LP Has $8.72 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Lyell Wealth Management LP cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 17.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 70,282 shares of the medical device company’s stock after selling 14,981 shares during the period. Lyell Wealth Management LP’s holdings in DexCom were worth $8,721,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Tokio Marine Asset Management Co. Ltd. lifted its position in DexCom by 3.3% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,703 shares of the medical device company’s stock valued at $1,204,000 after purchasing an additional 307 shares during the period. Atria Wealth Solutions Inc. lifted its position in DexCom by 73.9% during the 4th quarter. Atria Wealth Solutions Inc. now owns 6,290 shares of the medical device company’s stock valued at $781,000 after purchasing an additional 2,674 shares during the period. Harvest Fund Management Co. Ltd lifted its position in DexCom by 11.2% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 3,395 shares of the medical device company’s stock valued at $415,000 after purchasing an additional 343 shares during the period. GAMMA Investing LLC acquired a new stake in shares of DexCom in the 4th quarter valued at approximately $325,000. Finally, Linden Thomas Advisory Services LLC raised its position in shares of DexCom by 2.5% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 13,376 shares of the medical device company’s stock valued at $1,660,000 after acquiring an additional 330 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,375 shares of company stock valued at $25,530,859. 0.41% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

DexCom stock traded up $3.87 during mid-day trading on Wednesday, hitting $137.87. 3,236,645 shares of the company’s stock traded hands, compared to its average volume of 2,962,367. The firm has a 50 day simple moving average of $130.58 and a two-hundred day simple moving average of $117.88. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The stock has a market cap of $53.15 billion, a price-to-earnings ratio of 105.25, a P/E/G ratio of 2.26 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the firm posted $0.34 EPS. The company’s quarterly revenue was up 26.9% on a year-over-year basis. On average, research analysts expect that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on DXCM shares. Citigroup increased their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Raymond James increased their price target on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Royal Bank of Canada began coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. Finally, UBS Group increased their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $141.40.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.